Novartis CSPP100A2244
Posted by: Georgia Retina in
Research Title: Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema Sponsor: Novartis Principal Investigator: Robert Stoltz, M.D Ph.D Description: To evaluate the efficacy of oral Aliskiren on diabetic macular edema, as measured by improvement in OCT macular thickness after 12 weeks of therapy. Start Date: August 2009 Recruitment: Completed Project Personnel: Leslie Marcus, CCRC Location(s): Marietta; 114 Cherry St., Suite F,…
Read More
Ocriplasmin Research to Better Inform Treatment (ORBIT)
Posted by: Georgia Retina in
Research Title: This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes in 1500 patients recruited across approximately 120 USA retina sites. Sponsor: ThromboGenics Principal Investigator: Michael Jacobson, M.D. Description: The sites…
Read More OPH1002
Posted by: Georgia Retina in
Research Title: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration. Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: Subjects will be randomized in a 1:1 ratio to…
Read More Ophthotech OPH2003
Posted by: Georgia Retina in
Research Title: A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Sponsor: Ophthotech Corporation Principal Investigator: Atul Sharma, M.D. Description: The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura®…
Read More PDEX
Posted by: Georgia Retina in
Research Title: Triple Therapy — PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration Sponsor: Bay Area Retina Associates Principal Investigator: Atul Sharma, M.D. Description: The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of…
Read More AREDS2 ForeseeHome
Posted by: Georgia Retina in
Research Title: Home Vision Monitoring in Age-Related Eye Disease 2 (AREDS2) Using the ForeseeHome Device Sponsor: Notal Vision, Ltd. Principal Investigator: Jay Stallman, M.D. Description: The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection…
Read More C-09-067 RACE
Posted by: Georgia Retina in
Research Title: Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (AMD) Sponsor: Alcon Research Principal Investigator: Mark J. Rivellese, MD Description: The primary purpose of the study is to demonstrate a biological effect of AL-78898A after a single intravitreal injection. Start Date: November 2011 Recruitment: Completed Project Personnel: Leslie Marcus, CCRC Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084
Read More DRCR.net Protocol N
Posted by: Georgia Retina in
Research Title: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Sponsor: The Diabetic Retinopathy Clinical Research Network Principal Investigator: Robert Stoltz, M.D Ph.D Description: To determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic…
Read More Gemini GEM-NH-002 Clarity 2
Posted by: Georgia Retina in
Research Title: A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Variants of Complement Factor H (CFH) Sponsor: Gemini Therapeutics, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a prospective, multicenter, natural history (NH) study, conducted in subjects with non-central GA…
Read More Genentech GR39821
Posted by: Georgia Retina in
Research Title: A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. Sponsor: Genentech, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following…
Read More 
